Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Multicenter Extension Study to Further Evaluate Safety, Tolerability and Efficacy of Intracerebroventricular AX 250 Treatment in Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B) Patients

NCT05492799 is registered in ClinicalTrials.gov with Allievex Corporation as lead sponsor.

NCT NCT05492799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05492799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Multicenter Extension Study to Further Evaluate Safety, Tolerability and Efficacy of Intracerebroventricular AX 250 Treatment in Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B) Patients
Lead sponsor
Allievex Corporation
Phase
Phase 4
Overall status
Enrolling by invitation
Start date
December 2, 2022
Completion date
December 31, 2027
Enrollment
15 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

mps iii b